PFIZER Aktie

 

Düsseldorf (www.aktiencheck.de) - Pfizer-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) charttechnisch unter die Lupe. Auf der Suche nach eher defensiveren Anlagealternativen sollten sich Anlegerinnen und Anleger die Pfizer-Aktie genauer anschauen. [mehr]...

PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom....

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter....

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior....

The purchase adds an established hypertension brand to Novartis' cardiovascular range. Novartis India's board cleared the deal, after which the company signed an asset purchase agreement and trademark The post Novartis India acquires Pfizer brands for $132m appeared first on Pharmaceutical Business review....

Pfizer's 5.91% dividend yield anchors the story, and a pipeline finally catching a bid adds meaningful upside. My 24/7 Wall St. price target reflects that. Pfizer (NYSE:PFE) trades at $28.77 as of midday September 3, 2026. My 24/7 Wall St. price target is $32.72 over the next 12 months, implying 13.84% upside, with a buy […]...

The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead....

Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years....

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon?...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Bei Valneva ist wieder ordentlich Bewegung drin. Gestern legte die Aktie um +6,45% auf 2,99 € zu und gehörte damit zu den stärksten Werten am französischen Aktienmarkt. Eine neue Unternehmensmeldung gab es am Mittwoch zwar nicht. Der Blick richtet sich aber immer stärker auf den Borreliose-Impfstoff mit Pfizer und bei den Analysten liegen einige Kursziele weit […] The post Valneva-Aktie: Analysten sehen über +150% Potenzial first appeared on sharedeals.de....

Patient investors who buy the stock may be rewarded over the long term....

– Typewriter's site-specific, non-viral technology uses only LNP-delivered RNA to insert whole genes into the genome, to create safer, re-dosable, durable genetic medicines – – Matthew Stanton, PhD, and Leanne Peiser, DPhil, appointed CEO and CSO, respectively; former Pfizer CSO Mikael......

Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make....

Vier große Pharma-Namen, vier sehr verschiedene Bewertungen, und für Anleger entscheidet am Ende nicht die beste Bilanz, sondern der richtige Preis....

PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains....

Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously....

BRONX, N.Y.--(BUSINESS WIRE)--#Alzheimers--Oligomerix, Inc., a privately held, clinical-stage biotechnology company pioneering the development of novel small molecule therapeutics to address Alzheimer's disease (AD) and rare neurodegenerative diseases, today announced that Cara Cassino, M.D., has been appointed Interim President and Chief Executive Officer (CEO).Dr. Cassino has 25 years of clinical drug development and commercialization experience in both large pharma and biotech, with over 25 FDA/EMA drug approvals in a wide range of therapeutic areas. She has held senior leadership roles at Boehringer Ingelheim and Pfizer where she played an important role in the success of the blockbuster respiratory product Spiriva. She later joined Forest Laboratories (now part of Abbvie) as Senior Vice President of Clinical Development at a critical time in the company's evolution. She subsequently held C-suite positions in biotech, serving as Chief Medical Officer, EVP of Research & Development and Interim Co-CEO...